LENZ Therapeutics Files 8-K with Financials

TL;DR

LENZ Therapeutics filed an 8-K with financial statements and exhibits on Sept 30, 2025.

AI Summary

On September 30, 2025, LENZ Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a significant event. The company, formerly known as Graphite Bio, Inc. and Integral Medicines, Inc., is incorporated in Delaware and based in Solana Beach, California.

Why It Matters

This 8-K filing serves as a standard disclosure of financial statements and exhibits for LENZ Therapeutics, Inc., providing transparency to investors about the company's financial status.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial statements and exhibits, not indicating any immediate or significant operational or financial risks.

Key Players & Entities

• LENZ Therapeutics, Inc. (company) — Registrant
• September 30, 2025 (date) — Date of earliest event reported
• Graphite Bio, Inc. (company) — Former company name
• Integral Medicines, Inc. (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• Solana Beach, California (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.00001 — ich registered Common Stock, par value $0.00001 per share LENZ The Nasdaq Stock Market

Filing Documents

• lenz-20250930.htm (8-K) — 29KB
• exhibit991-93025vizzavaila.htm (EX-99.1) — 20KB
• lenzlogoa.jpg (GRAPHIC) — 3KB
• 0001815776-25-000062.txt ( ) — 178KB
• lenz-20250930.xsd (EX-101.SCH) — 2KB
• lenz-20250930_lab.xml (EX-101.LAB) — 23KB
• lenz-20250930_pre.xml (EX-101.PRE) — 13KB
• lenz-20250930_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 30, 2025 , LENZ Therapeutics, Inc. ( " LENZ " ) issued a press release announcing the availability of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop approved in the United States by the U.S. Food and Drug Administration ( " FDA " ) for the treatment of presbyopia in adults. A copy of the press release is furnished herewith as Exhibit 99.1 . The information contained in Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly provided by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. As set forth above, on September 30, 2025, LENZ announced that VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by LENZ's sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through LENZ's ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated September 30 , 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 30, 2025 LENZ THERAPEUTICS, INC. By: /s/ Daniel Chevallard Name: Daniel Chevallard Title: Chief Financial Officer (Principal Financial and Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR